Shire PLC (LON:SHP) was upgraded by analysts at HSBC Holdings plc to a “hold” rating in a report issued on Thursday, reports. The brokerage currently has a GBX 4,450 ($57.64) price target on the biopharmaceutical company’s stock. HSBC Holdings plc’s price target would indicate a potential upside of 2.90% from the stock’s current price.

A number of other equities analysts have also recently issued reports on SHP. Barclays PLC started coverage on shares of Shire PLC in a research report on Wednesday, March 8th. They set an “overweight” rating and a GBX 6,500 ($84.20) price objective for the company. Liberum Capital restated a “buy” rating and issued a GBX 5,500 ($71.24) price target on shares of Shire PLC in a research report on Thursday, March 9th. Royal Bank Of Canada restated an “outperform” rating on shares of Shire PLC in a research report on Monday, March 13th. Goldman Sachs Group, Inc. (The) reaffirmed a “conviction-buy” rating and issued a GBX 6,800 ($88.08) price objective on shares of Shire PLC in a research note on Thursday, March 16th. Finally, J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a GBX 6,000 ($77.72) price objective on shares of Shire PLC in a research note on Tuesday, March 21st. Two research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of GBX 6,005.60 ($77.79).

Shares of Shire PLC (LON:SHP) traded up 1.59% during trading on Thursday, hitting GBX 4324.50. The stock had a trading volume of 1,685,365 shares. The stock’s 50 day moving average is GBX 4,526.50 and its 200-day moving average is GBX 4,615.89. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00. The company’s market cap is GBX 39.27 billion.

WARNING: “Shire PLC (LON:SHP) Stock Rating Upgraded by HSBC Holdings plc” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at

In other Shire PLC news, insider Dominic Blakemore acquired 152 shares of the company’s stock in a transaction on Friday, June 30th. The shares were purchased at an average cost of GBX 4,255 ($55.12) per share, with a total value of £6,467.60 ($8,377.72).

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (LON:SHP)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with's FREE daily email newsletter.